Preventing a second stroke begins soon after the initial event, but secondary prevention continues well beyond hospital discharge. The treatment plan can vary depending on the type and cause of the stroke, the patient’s vascular risk factors, comorbidities, and potential treatment risks.
Major components of secondary prevention can include:
The treatment landscape for secondary stroke prevention continues to evolve, with growing attention to individualized treatment, risk-factor management, and emerging approaches to preventing recurrent ischemic events.
Understanding both established and emerging therapies can help clinicians navigate long-term secondary prevention while balancing the risk of recurrent stroke with potential treatment complications.
Antithrombotics help prevent clot formation or growth and include antiplatelet agents and anticoagulants. Although thrombolytic medications also affect blood clots, they work by actively breaking down existing clots and are primarily used in acute treatment rather than long-term secondary prevention.
Knowing the stroke etiology is critical for choosing the right antithrombotic agents.
For selected patients with minor non-cardioembolic ischemic stroke or high-risk TIA, short-term dual antiplatelet therapy (DAPT) can reduce the risk of early recurrent stroke. A common regimen combines aspirin and clopidogrel and is initiated soon after the event (often within 12 to 24 hours). Treatment duration varies based on the patient’s clinical circumstances, but DAPT is generally not continued long term because the risk of bleeding increases with prolonged use.
Ticagrelor combined with aspirin is another short-term option for selected patients, including some patients with minor ischemic stroke or high-risk TIA. When combining the two drugs, the maintenance dose of aspirin should not exceed 100 milligrams (mg) per day, as higher doses reduce ticagrelor’s effectiveness. Clinical trial data have also evaluated this approach in patients with CYP2C19 loss-of-function alleles that can affect clopidogrel metabolism.
As patients transition into long-term prevention, treatment for non-cardioembolic ischemic stroke is typically a daily 75 mg dose of clopidogrel, aspirin (50-325 mg daily), or aspirin (25 mg) and extended-release dipyridamole (200 mg) taken twice daily.
For patients whose stroke is associated with atrial fibrillation or another indication for anticoagulation, long-term anticoagulant therapy is generally used when there are no contraindications. Direct oral anticoagulants (DOACs) are generally preferred over warfarin for most patients with nonvalvular atrial fibrillation, while warfarin remains important for certain patients, including those with mechanical heart valves.
When selecting treatment, providers must balance preventing recurrent thrombosis, avoiding high-risk bleeding, and managing other patient-specific risks.
While antithrombotic treatment is the standard for secondary stroke prevention, increasing the intensity of this approach may not be appropriate for every patient.
Researchers are exploring new targets in the coagulation pathway, including Factor XI/XIa inhibitors.
Factor XI/XIa inhibitors are an emerging class of anticoagulants designed to “uncouple” pathological clot formation from the bleeding risks associated with traditional anticoagulants. Factor XI is a liver-made blood protein that helps blood form clots. It is inactive (a zymogen) until the body needs it to stop bleeding or when a harmful clot forms. Factor XIa is the active form of Factor XI and helps create more thrombin, a chemical that turns liquid blood into a solid plug.
One example of this emerging approach is asundexian, an oral Factor XIa inhibitor being investigated for secondary prevention following non-cardioembolic ischemic stroke or high-risk TIA.
In the Phase 3 OCEANIC-STROKE clinical trial, researchers evaluated whether adding asundexian to planned antiplatelet therapy could reduce recurrent ischemic stroke without increasing major bleeding. The study included 12,327 patients who were enrolled within 72 hours of a non-cardioembolic ischemic stroke or a high-risk TIA. Participants took either 50 mg of asundexian once daily or a placebo, alongside their planned antiplatelet therapy.
Over a median follow-up of 19 months, the findings revealed a lower stroke risk, with ischemic stroke occurring in 6.2 percent of the asundexian group compared to 8.4 percent of the placebo group. Rates of major bleeding were not significantly different between groups (1.9 percent for asundexian vs. 1.7 percent for placebo). Additionally, the risk of composite events — such as cardiovascular death or myocardial infarction — was also lower with asundexian.
The results add to the evidence evaluating Factor XIa inhibition as an approach to secondary stroke prevention. However, the findings apply to the population and treatment strategy studied in OCEANIC-STROKE and do not establish a role for asundexian in all stroke survivors.
Antithrombotic therapy is an important component of secondary stroke prevention, but it is only one part of long-term risk reduction. Clinicians should also address modifiable vascular risk factors and underlying conditions that can contribute to recurrent stroke.
Other preventive measures may include:
As new antithrombotic strategies emerge, these foundational approaches remain essential to secondary stroke prevention.
A patient’s treatment needs can evolve after the initial stroke. New diagnoses, recurrent events, bleeding events from antithrombotics, kidney disease, medication intolerance, or changes in cardiovascular risk may require clinicians to reassess the treatment plan.
Clinicians must also balance pharmacological stroke prevention with the management of common comorbidities, such as diabetes, chronic kidney disease, and heart failure. Because polypharmacy increases the risk of drug-drug interactions, adverse events, and non-adherence, balancing these treatment regimens carefully can be a delicate tightrope for clinicians.
Throughout the treatment journey, clinicians should reassess whether the treatment plan remains appropriate rather than treating secondary prevention as a static prescription. But this process shouldn’t fall solely on the clinician — patients and care partners should help weigh benefits, risks, adherence, and treatment goals.
Researchers and clinicians are increasingly interested in more targeted approaches to thrombosis prevention. Continued investigation of therapies for secondary stroke prevention may alter the balance between ischemic protection and bleeding. There’s also increased emphasis on aligning treatment to stroke mechanism and a patient’s individual risk for bleeding or other events.
Emerging therapies, such as Factor XIa inhibition, are expanding the research landscape in secondary stroke prevention. As these therapies continue to be studied, questions about patient selection, long-term efficacy, safety, and integration with existing treatment strategies will remain important.
Preventing a second stroke is not one treatment or one decision. It requires an evolving combination of pharmacologic therapies, risk-factor control, and reassessment over time. New research in emerging therapeutic targets may expand future options for patients, but those approaches must still be considered alongside the established foundation of secondary prevention.
By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!